The prognostic value of ERCCI and RRMI gene expression in completely resected non-small cell lung cancer: Tumor recurrence and overall survival

Cancer Management and Research

Volumn 5, Issue 1, 2013, Pages 327-336

  Tantraworasin, Apichat ^a   Saeteng, Somcharoen ^a   Lertprasertsuke, Nirush ^a   Arayawudhikul, Nuttapon ^b   Kasemsarn, Choosak ^c   Patumanond, Jayanton ^a  

^a CHIANG MAI UNIVERSITY   (Thailand)

^b LAMPANG HOSPITAL   (Thailand)

^c Cardiovascular Thoracic Unit   (Thailand)

Author keywords

ERCC1; NSCLC; Prognostic factor; RRM1; Tumor recurrence

Indexed keywords

DOCETAXEL; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; RIBONUCLEOTIDE REDUCTASE;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG TREATMENT FAILURE; ERCC1 GENE; FEMALE; GENE EXPRESSION; GENE FUNCTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LYMPH NODE DISSECTION; LYMPHADENOPATHY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; METASTASIS; ONCOGENE; OVERALL SURVIVAL; PATHOLOGY; PREDICTIVE VALUE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; RRM1 GENE; SURVIVAL TIME; THAILAND; TREATMENT OUTCOME; TUMOR INVASION; TUMOR NECROSIS; TUMOR RECURRENCE; VASCULAR TUMOR;

EID: 84885084305     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S52073     Document Type: Article

References (33)

1. Besse B, Olaussen KA, Soria JC. ERCC1 and RRM1: ready for prime time? J Clin Oncol. 2013;31(8):1050-1060.
2. Fisher LA, Samson L, Bessho T. Removal of reactive oxygen species-induced 3′-blocked ends by XPF-ERCC1. Chem Res Toxicol. 2011; 24(11):1876-1881.
3. McVey M, Lee SE. MMEJ repair of double-strand breaks (director's cut): deleted sequences and alternative endings. Trends Genet. 2008; 24(11):529-538.
4. Wang X, Zhao J, Yang L, et al. Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer. Med Oncol. 2010;27(2):484-490.
5. Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol. 2006;17(12):1818-1825.
6. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 2002;8(7): 2286-2291.
7. Pitterle DM, Kim YC, Jolicoeur EM, Cao Y, O'Briant KC, Bepler G. Lung cancer and the human gene for ribonucleotide reductase subunit M1 (RRM1). Mamm Genome. 1999;10(9):916-922.
8. Jordheim L P, Sève P, Trédan O, Dumontet C. The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol. 2011;12(7):693-702.
9. Bepler G, Kusmartseva I, Sharma S, et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol. 2006;24(29):4731-4737.
10. Reynolds C, Obasaju C, Schell MJ, et al. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol. 2009;27(34):5808-5815.
11. Goldstraw P, editor. IASLC Staging Manual in Thoracic Oncology. Orange Park, FL: Editorial Rx Press John Wiley & Sons Ltd; 2009.
12. Goldstraw P. The 7th Edition of TNM in Lung Cancer: what now? J Thorac Oncol. 2009;4(6):671-673.
13. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC, editors. World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004.
14. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244-285.
15. Tantraworasin A, Saeteng S, Lertprasertsuke N, Arreyakajohn N, Kasemsarn C, Patumanond J. Prognostic factors of tumor recurrence in completely resected non-small cell lung cancer. Cancer Manag Res. 2013;5:77-84.
16. Vilmar AC, Santoni-Rugiu E, Sørensen JB. ERCC1 and histopathology in advanced NSCLC patients randomized in a large multi center phase III trial. Ann Oncol. 2010;21(9):1817-1824.
17. Tepeli E, Caner V, Büyükpi{dotless}narbaşi{dotless}li{dotless} N, et al. Expression of ERCC1 and its clinicopathological correlations in non-small cell lung cancer. Mol Biol Rep. 2012;39(1):335-341.
18. Pesta M, Kulda V, Fiala O, et al. Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer. Anticancer Res. 2012;32(11):5003-5010.
19. Olaussen KA, Dunant A, Fouret P, et al; IALT Bio Investigators. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355(10):983-991.
20. Lee KH, Min HS, Han S W, et al. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer. 2008;60(3):401-407.
21. Bepler G, Olaussen KA, Vataire AL, et al. ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis. Am J Pathol. 2011;178(1):69-78.
22. Custodio AB, González-Larriba JL, Bobokova J, et al. Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer. J Thorac Oncol. 2009;4(7):891-910.
23. Booton R, Ward T, Ashcroft L, Morris J, Heighway J, Thatcher N. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol. 2007;2(10):902-906.
24. Roth JA, Carlson JJ. Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Clin Lung Cancer. 2011;12(6):393-401.
25. Friboulet L, Olaussen KA, Pignon J P, et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med. 2013;368(12):1101-1110.
26. Winton T, Livingston R, Johnson D, et al. National Cancer Institute of Canada Clinical Trials Group: National Cancer Institute of the United States Inter group JBR 10 Trial Investigators. Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352(25):2589-2597.
27. Pignon J P, Tribodet H, Scagliotti G V, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. Jul 20, 2008;26(21):3552-3559.
28. Bepler G, Gautam A, McIntyre LM, et al. Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer. J Clin Oncol. 2002;20(5):1353-1360.
29. Gautam A, Li ZR, Bepler G. RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene. 2003;22(14): 2135-2142.
30. Bepler G, Sharma S, Cantor A, et al. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol. 2004;22(10):1878-1885.
31. Bepler G, Williams C, Schell MJ, et al. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2013;31(19):2404-2412.
32. Gong W, Zhang X, Wu J, et al. RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis. Lung Cancer. 2012;75(3):374-380.
33. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med. 2007;356(8):800-808.